🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chongqing
Clinical trial register · China

Clinical Trials in Chongqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca99 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC38 First Affiliated Hospital of Chongqing Medical University37 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chongqing

1056 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Steroids-Based Screening for Primary Aldosteronism
NCT06941116Primary Aldosteronism, Hypertension
Qifu Li
Observational
406
Chongqing
2025-04-15
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
DrugsLM-108·Penpulimab·Gemcitabine Hydrochloride·Paclitaxel
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Jinan
2025-04-09
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
Child-Parent Familial Hypercholesterolemia Screening
NCT04529967Familial Hypercholesterolemia
Children's Hospital of Fudan University
Observational
15,000
Hefei, Qidong, Shanghai, Taiyuan, Chongqing, Ürümqi
2025-04-01
Active, closed
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
NCT06950164Preterm, Ductus Arteriosus
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
200
Chongqing
2025-04-01
Not yet open
Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
NCT06812546Heart Failure, Acute Myocardial Infarction (AMI), Acute Heart Failure (AHF)
DrugVericiguat
Dongying Zhang
Phase 4
200
Chongqing
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
DrugOlverembatinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
NCT07217600Radiotherapy-induced Nausea and Vomiting (RINV), Pediatric Cancer
Chongqing University Cancer Hospital
Phase 4
60
Chongqing
2025-03-25
Active, closed
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
NCT06940921Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal Metastasis
DrugCadonilimab
Zhang Tao
Phase 1/2
26
Chongqing
2025-03-20
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
256
Hefei, Beijing, Chongqing, Foshan, Jiangmen, Liuzhou, Yulin, Cangzhou
2025-03-17
Active, closed
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06834672Ovarian, Primary Peritoneal, Fallopian Tube Cancer
DrugIBI354
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
450
Chongqing
2025-03-17
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Carboplatin
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
By invitation
Exploration of Repeated High-frequency Transcranial Magnetic Stimulation for the Treatment of Acute Phase Aphasia in Post-stroke Patients
NCT06787508Stroke, Aphasia, Control Patients
First Affiliated Hospital of Chongqing Medical University
Not applicable
70
Chongqing
2025-03-15
Recruiting
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
NCT06798207Gynecological Tumors
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Active, closed
Exploring the Optimal Concentration of Lidocaine Test Dose for Labor Analgesia
NCT06819579Labor Pain
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
99
Chongqing
2025-03-10
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Recruiting
A Prospective Cohort Study on Primary Cutaneous Amyloidosis
NCT06998875Primary Cutaneous Amyloidosis
Army Medical University, China
Phase 4
56
Chongqing
2025-03-01
Recruiting
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
NCT06978829LA HNSCC
DrugsPemetrexed·Tislelizumab
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
42
Chongqing
2025-03-01
Not yet open
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979Obesity
DrugsWegovy·Semaglutide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
408
Hefei, Xuancheng, Chongqing, Fuzhou, Lanzhou, Guilin, Liuzhou, Nanning
2025-03
Recruiting
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
NCT06848465Colorectal Cancer, Liver Metastasis, LDRT
DrugsXelox·Tislelizumab
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1
9
Chongqing
2025-02-28
Recruiting
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
NCT07027280Head and Neck Cancer
First Affiliated Hospital of Chongqing Medical University
Observational
700
Chongqing
2025-02-27
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients
NCT07051694Sepsis
Third Military Medical University
Not applicable
60
Chongqing
2025-02-27
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsAtezolizumab·Etoposide·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
NCT06848699Solid Tumor Cancer, Non Small Cell Lung Cancer
DrugsHLX43 4·HLX43 3·HLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 1/2
105
Hunan, Jinan, Chongqing
2025-02-25
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
DrugsIBI363·Pembrolizumab
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Not yet open
The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function
NCT06775366Cognitive Functioning, Propofol, Remimazolam, Circadian Rhythm
DrugsRemimazolam·Propofol
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
174
Chongqing
2025-02-24
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Recruiting
Effect of Remote Local Peripheral Nerve Cooling on Pain of Arterial Puncture
NCT06838572Acute Pain
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
100
Chongqing
2025-02-15
Recruiting
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
NCT06718543Rectal Cancer
DrugCapeox
fan li
Phase 2
100
Chongqing
2025-02-10
Recruiting
Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
NCT06796920Adrenomyeloneuropathy Without Cerebral Involvement
Third Military Medical University
Not applicable
10
Beijing, Chongqing, Jingmen
2025-02-10
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
NCT06791538Gastric Cancer, Gastroesophageal Junction Cancer
Southwest Hospital, China
Not applicable
740
Chongqing
2025-02-01
Not yet open
AZA Combined with R-GemOx for Elderly DLBCL Patients
NCT06778902DLBCL - Diffuse Large B Cell Lymphoma
DrugsR-GemOx·Azacytidine
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
80
Chongqing
2025-02-01
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Active, closed
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
NCT06812117Diabetic Peripheral Neuropathic Pain
Daiichi Sankyo
Observational
721
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2025-01-24
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540Atopic Dermatitis
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Active, closed
Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes Mellitus
NCT06587438Diabetes Mellitus
Sinocare
Not applicable
160
Beijing, Chongqing, Shunde, Wuhan, Jinan, Shanghai
2025-01-17
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029HER2-positive Breast Cancer
DrugTrastuzumab emtansine
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
NCT06766266Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University
Phase 1
18
Chongqing
2025-01-10
Active, closed
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336Non Small Cell Lung Cancer
DrugsUliledlimab·Gemcitabine·Pemetrexed·Cisplatin
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Active, closed
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485Congenital Hemophilia A
CSL Behring
Phase 3
60
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Tangshan, Tianjin
2025-01-09
Recruiting
The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery
NCT06743802Postoperative Pain
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
264
Chongqing
2025-01-09
Recruiting
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
NCT06955286Primary Aldosteronism, Autonomous Cortisol Secretion, Adrenal Insufficiency
Qifu Li
Observational
521
Chongqing
2025-01-02
Active, closed
Effectiveness of Urethral Stent Irrigation in Preventing Surgical Site Infections in Adolescents With Hypospadias
NCT06520423Hypospadias
Xing Liu
Not applicable
150
Chongqing
2025-01-02
Active, closed
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer
NCT06868758HER2 Positive Breast Carcinoma, Neoadjuvant Therapy
Chongqing General Hospital
Observational
50
Chongqing
2025-01-01
Active, closed
Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial Carcinoma
NCT06993779UTUC
Mingzhao Xiao
Observational
1,000
Chongqing
2025-01-01
Recruiting
Application of Single-Port Robot-Assisted Breast-Conserving Surgery Via Axillary Approach for Breast Cancer.
NCT06738654Invasive Breast Carcinoma
Xu Yan
Not applicable
64
Chongqing
2024-12-31
By invitation
The Application Value of Intercostal Suturing in Preventing Postoperative Thoracoscopic Lung Resection Chest Wall Pulmonary Hernia
NCT06924515VATS, Lung Hernia
Mingjian Ge
Not applicable
104
Chongqing
2024-12-24
Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
NCT07251309Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
Risk Factors for Complications After Cranioplasty
NCT06740773Cranioplasty, Postoperative Complications, Risk Assessment
Qilu Hospital of Shandong University
Observational
1,000
Chongqing, Xi'an, Jinan
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
Active, closed
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
NCT06829329Chronic Hepatitis B
DrugAHB-137
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Recruiting
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032Advanced Endometrial Cancer
DrugsFruquintinib·Doxorubicin·Paclitaxel·Tislelizumab
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
NCT05230914Stroke, Ischemic, Stroke, Acute
Xinqiao Hospital of Chongqing
Not applicable
1,846
Wuhu, Chongqing, Jiangmen, Haikou, Huai'an, Wuxi, Jingdezhen, Dalian
2024-12-12
Recruiting
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
NCT06643754Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
115
Chongqing
2024-12-10
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
DrugSAR441566
Sanofi
Phase 2
260
Changzhou, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanchang, Shanghai
2024-12-10
Active, closed
Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy
NCT07312682Lung Neoplasms, Radiation Pneumonitis
The Second Affiliated Hospital of Chongqing Medical University
Observational
202
Chongqing
2024-12-09
Recruiting
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06686745Advanced Solid Tumors
DrugOlaparib
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Shanghai, Chongqing
2024-12-06
Active, closed
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
NCT06706310Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
Identification of Microplastics in Liver, Stomach, Blood, and Feces of Obese Patients and Their Association Analysis with Macrogenomics and Metabolomics.
NCT06826586Obesity and Overweight
First Affiliated Hospital of Chongqing Medical University
Observational
20
Chongqing
2024-12-01
Active, closed
The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer
NCT06856382Gastric Cancers
Dong Peng
Observational
20
Chongqing
2024-12-01
Active, closed
Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer
NCT07063550Colorectal Cancer (MSI-H), Microplastic Exposure
Dong Peng
Observational
100
Chongqing
2024-12-01
Recruiting
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
NCT06760858Gastric Cancer, Gastroesophageal Junction Cancer
DrugTislelizumab
Southwest Hospital, China
Observational
122
Chongqing
2024-12-01
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
DrugsTaletrectinib·Crizotinib
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06767800Gastroesophageal Adenocarcinoma
DrugsTQB2102·Penpulimab·Etoposide
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169Graft-versus-host Disease
DrugsRovadicitinib·Mycophenolate Mofetil·Imatinib·Methotrexate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
NCT07349654Liver Cirrhosis, Variceal Bleeding, Cirrhosis, Ascites Hepatic, Hepatic Encephalopathy (HE)
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
72
Chongqing, Qianjiang
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Active, closed
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
NCT06621654Haemophilus Influenzae Type B Infection
CanSino Biologics Inc.
Phase 1
160
Chongqing
2024-11-15
Active, closed
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Locally Advanced or Metastatic Breast Cancer
DrugsSIM0270·Exemestane·Everolimus·Fulvestrant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860Atopic Dermatitis
DrugICP-332
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Rows per page Showing 401–500 of 1056
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/chongqing?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,056 of those studies with a site in Chongqing.

How many clinical trials are recruiting in Chongqing?

589 of the 1,056 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 118 have not yet opened recruitment, 334 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.